GENERALI INVESTMENTS PARTNERS: TIM RAINSFORD APPOINTED NEW GLOBAL HEAD OF SALES

Milan – Generali Investments Partners S.p.A. Società di gestione del risparmio (GIP) announces the appointment of Tim Rainsford as new Global Head of Sales. In this role, he will be responsible for defining the commercial development plans and strategies aimed at strengthening Generali Investments’ positioning in key markets, as well as growing its international footprint by expanding into new geographies.

Generali Investments Partners S.p.A. Società di gestione del risparmio (GIP) announces the appointment of Tim Rainsford as new Global Head of Sales. In this role, he will be responsible for defining the commercial development plans and strategies aimed at strengthening Generali Investments’ positioning in key markets, as well as growing its international footprint by expanding into new geographies. 

In his new position, effective as of September 1st, Tim will report to Carlo Trabattoni, CEO of Generali Investments Partners, and will lead a global team of sales professionals based in Italy, France and Germany. 

Tim brings to Generali Investments Partners over 20 years of experience in senior roles in the asset management industry and an authoritative expertise in customer relationship management, gained by globally coordinating international sales, marketing and client service teams. Before joining GIP, Tim was Group Head of Distribution and Marketing at GAM Investments, with the responsibility for the company’s marketing and sales strategic direction. He previously spent thirteen years at Man Investments Ltd, covering positions of growing responsibility including Senior Managing Director – Head of European Sales, and Global Co-Head of Sales and Marketing.

TIM RAINSFORD APPOINTED NEW GLOBAL HEAD OF SALES

RELATED INSIGHTS

COVID-19 FACTS & FIGURES
According to the IMF’s Managing Director, strong international cooperation on coronavirus vaccine could speed up the world economic recovery and add $9 trillion to global income by 2025. A WHO trial found that Remdesivir, Hydroxychloroquine, Lopinavir and Interferon have little or no effect on hospitalized Covid-19 patients. Gilead Sciences has questioned the findings of the WHO study saying data appeared inconsistent.
INCORPORATING QUANT SIGNALS INTO EU EQUITY SECTOR/STYLE STRATEGY: MAINTAIN A TILT TO CYCLICALS AND VALUE
We present an update of our proprietary equity valuation tool, based on quant models. It provides indications of over- or undervaluation for different sectors and styles of European equities, which is further enriched by our qualitative analysis. Currently, among European equity sectors, financials, energy, telecoms, and autos look undervalued while Pharma, utilities and software appear overvalued.
CHINA’S RECOVERY CONTINUED BUT A BIT SOFTER THAN EXPECTED
China's economic recovery continued in Q3 2020, although a bit softer than expected. Real GDP growth rose to 4.9% yoy, slightly below the Reuters consensus expectation of 5.2% yoy, but still a substantial upturn from the 3.2% yoy in Q2. On a quarterly base, growth dynamics softened to 2.7% qoq, after 11.7% qoq and -10% qoq in the two previous quarters.
LOAD MORE